| abstract |
PROBLEM TO BE SOLVED: To provide a method for treating cancer resistant to ErbB therapy. Provided herein are methods for treating a cancer that is resistant to treatment with an anti-ErbB therapeutic and is associated with an activated MET gene mutation or MET gene amplification. In this method, a combination of an anti-ErbB therapeutic and an anti-MET therapeutic is administered to a subject. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in cancer cells. In certain embodiments, the cancer can be, for example, lung cancer, brain cancer, breast cancer, head and neck cancer, colon cancer, ovarian cancer, gastric cancer, or pancreatic cancer. In an exemplary embodiment, the cancer is non-small cell lung cancer (NSCLC). [Selection] Figure 6 |